Syra Health Corp - 2025年度报告

FORM 10-K ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2025 Commission File Number 001-41822 85-4027995 Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes☐No☒ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes☐No☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will notbe contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smallerreporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectivenessof its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of theregistrant included in the filing reflect the correction of an error to previously issued financial statements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-basedcompensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant was approximately$979,537as of June 30, 2025. The number of shares of the registrant’s Class A Common Stock outstanding as of March 12, 2026 was 11,339,169. Documents Incorporated by Reference: Specified portions of the registrant’s proxy statement, which will be filed with the Securities and Exchange Commission pursuant toRegulation 14 A in connection with the registrant’s 2025 Annual Meeting of Stockholders (the “Proxy Statement”), are incorporated by PART IIIDirectors, Executive Officers and Corporate Governance Cautionary Note Regarding Forward-Looking Statements This Annual Report on Form 10-K contains forward-looking statements that involve risks and uncertainties. You should not placeundue reliance on these forward-looking statements. All statements other than statements of historical facts contained in this AnnualReport on Form 10-K are forward-looking statements. The forward-looking statements in this Annual Report on Form 10-K are onlypredictions. In some cases, you can identify these forward-looking statements by terms such as “anticipate,” “believe,” “continue,”“could,” “depends,” “estimate,” “expects,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,”“would” or the negative of those terms or other similar expressions, although not all forward-looking statements contain those words. ●our projected financial position and estimated cash burn rate; ●our estimates regarding expenses, future revenues and capital requirements; ●our ability to continue as a going concern; ●our need to raise substantial additional capital to fund our operations; ●our ability to compete in the healthcare industry; ●the timing, cost and success or failure of new product and service introductions, development and product upgrade releases; ●competitive pressures including offerings and pricing; ●our ability to establish and maintain strategic relationships; ●undetected errors or similar problems in our software products; ●compliance with existing laws, regulations and industry initiatives and future changes in laws or regulations in the healthcareindustry; ●the